Efficacy and safety of lipegfilgrastim versus pegfilgrastim: A randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
Số trang: 12
Loại file: pdf
Dung lượng: 698.12 KB
Lượt xem: 9
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Lipegfilgrastim is a novel glyco-pegylated granulocyte-colony stimulating factor in development for neutropenia prophylaxis in cancer patients receiving chemotherapy. This phase III, double-blind, randomized, active-controlled, noninferiority trial compared the efficacy and safety of lipegfilgrastim versus pegfilgrastim in chemotherapy-naïve breast cancer patients receiving doxorubicin/docetaxel chemotherapy.
Nội dung trích xuất từ tài liệu:
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: A randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
Nội dung trích xuất từ tài liệu:
Efficacy and safety of lipegfilgrastim versus pegfilgrastim: A randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Febrile neutropenia Breast cancer Recombinant granulocyte-colony stimulating factor Docetaxel chemotherapyGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 167 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 109 0 0 -
12 trang 87 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 35 0 0
-
11 trang 35 0 0
-
12 trang 33 0 0